News
BNTC
11.25
+15.98%
1.55
Benitec reports Q2 results
Seeking Alpha · 16h ago
Benitec Biopharma Inc <BNTC.OQ> expected to post a loss of 77 cents a share - Earnings Preview
Reuters · 17h ago
BENITEC BIOPHARMA INC: QTRLY LOSS PER SHARE $0.33
Reuters · 18h ago
BENITEC BIOPHARMA INC <BNTC.O> Q2 SHR VIEW $-0.77 -- LSEG IBES DATA
Reuters · 18h ago
BENITEC BIOPHARMA Q2 NET INCOME USD -7.4 MILLION
Reuters · 18h ago
*Benitec Biopharma 2Q Loss $7.36M >BNTC
Dow Jones · 18h ago
*Benitec Biopharma 2Q Loss/Shr 33c >BNTC
Dow Jones · 18h ago
Press Release: Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
Dow Jones · 18h ago
Press Release: Benitec Biopharma Releases Second -2-
Dow Jones · 18h ago
BENITEC BIOPHARMA ANNOUNCES ACCEPTANCE OF LATE- BREAKING ORAL ABSTRACT FOR THE BB-301 PHASE 1B/2A CLINICAL STUDY AT THE MUSCULAR DYSTROPHY ASSOCIATION CLINICAL AND SCIENTIFIC CONFERENCE
Reuters · 18h ago
Validea Kenneth Fisher Strategy Daily Upgrade Report - 2/14/2025
NASDAQ · 20h ago
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
Barchart · 1d ago
Weekly Report: what happened at BNTC last week (0203-0207)?
Weekly Report · 4d ago
Weekly Report: what happened at BNTC last week (0127-0131)?
Weekly Report · 02/03 12:00
Weekly Report: what happened at BNTC last week (0120-0124)?
Weekly Report · 01/27 12:04
Weekly Report: what happened at BNTC last week (0113-0117)?
Weekly Report · 01/20 11:52
Benitec Biopharma: Early Positive Data, Small Target Market, Little Competition
Seeking Alpha · 01/20 10:40
Weekly Report: what happened at BNTC last week (0106-0110)?
Weekly Report · 01/13 11:54
Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock
Barchart · 01/13 10:04
Weekly Report: what happened at BNTC last week (1230-0103)?
Weekly Report · 01/06 12:04
More
Webull provides a variety of real-time BNTC stock news. You can receive the latest news about Benitec Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About BNTC
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.